Prosecution Insights
Last updated: April 19, 2026

BIONTECH SE

7 pending office actions

Portfolio Summary

7
Total Pending OAs
2
Final Rejections
5
Non-Final OAs

Pending Office Actions

App #TitleExaminerArt UnitStatusFiled
18334820 TISSUE-SPECIFIC ANTIGENS FOR CANCER IMMUNOTHERAPY ROONEY, NORA MAUREEN 1641 Non-Final OA Jun 14, 2023
18311155 NEOANTIGENS AND METHODS OF THEIR USE ALLEN, MICHAEL D 1671 Non-Final OA May 02, 2023
18007024 T CELL MANUFACTURING COMPOSITIONS AND METHODS JUEDES, AMY E 1644 Non-Final OA Jan 26, 2023
17495571 METHOD AND SYSTEMS FOR PREDICTION OF HLA CLASS II-SPECIFIC EPITOPES AND CHARACTERIZATION OF CD4+ T CELLS SABOUR, GHAZAL 1686 Non-Final OA Oct 06, 2021
17599468 COMPOSITIONS AND METHODS FOR PREPARING T CELL COMPOSITIONS AND USES THEREOF FAUST, AMBER KATHLEEN 1643 Final Rejection Sep 28, 2021
17481781 CORONAVIRUS VACCINES AND METHODS OF USE STUART, CAREY ALEXANDER MC 1671 Final Rejection Sep 22, 2021
17253922 NEOANTIGENS AND USES THEREOF SANG, HONG 1646 Non-Final OA Dec 18, 2020

Managing BIONTECH SE's Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month